The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice

Vaccine

Volumn 28, Issue 23, 2010, Pages 3913-3919

  Chen, Xiaohua ^a   Lai, Jinglan ^a   Pan, Qingchun ^a   Tang, Zhenghao ^a   Yu, Yongsheng ^a   Zang, Guoqing ^a  

^a Shanghai No 6 People's Hospital   (China)

Author keywords

Cytotoxic T lymphocyte; HBV core antigen; HBV transgenic mouse; Tat PTD; Virus immunotherapy

Indexed keywords

GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; HEPATITIS B CORE ANTIGEN TAT PROTEIN TRANSDUCTION DOMAIN FUSION PROTEIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE COMPARISON; HEPATITIS B; HEPATITIS B VIRUS; HUMORAL IMMUNITY; INTERFERON PRODUCTION; LIVER HISTOLOGY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SPLEEN CELL; TRANSGENIC MOUSE; VIRUS INHIBITION; VIRUS LOAD;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HEPATITIS ANTIBODIES; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; LIVER; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; RECOMBINANT FUSION PROTEINS; SPLEEN; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 77952421309     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.03.070     Document Type: Article

References (35)

1. Ganem D., and Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350 11 (2004) 1118-1129
2. Williams R. Global challenges in liver disease. Hepatology 44 3 (2006) 521-526
3. Seeger C., and Mason W.S. Hepatitis B virus biology. Microbiol Mol Biol Rev 64 (2000) 51-68
4. Raney A.K., Hamatake R.K., and Hong Z. Agents in clinical development for the treatment of chronic hepatitis B. Expert Opin Invest Drugs 12 8 (2003) 1281-1295
5. Löhr H.F., Krug S., Herr W., Weyer S., Schlaak J., Wölfel T., et al. Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B. Liver 18 6 (1998) 405-413
6. Bertoletti A., Maini M., and Williams R. Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res 60 2 (2003) 61-66
7. Li X., Yang X., Li L., Liu H., and Liu J. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine. Vaccine 24 16 (2006) 3321-3331
8. Zhang Y., Li S., Shan M., Pan X., Zhuang K., He L., et al. Hepatitis B virus core antigen epitopes presented by HLA-A2 single-chain trimers induce functional epitope-specific CD8+ T-cell responses in HLA-A2.1/Kb transgenic mice. Immunology 121 1 (2007) 105-112
9. You H., Liu Y., Cong M., Ping W., You C., Zhang D., et al. HBV genes induce cytotoxic T-lymphocyte response upon adeno-associated virus (AAV) vector delivery into dendritic cells. J Viral Hepat 13 9 (2006) 605-612
10. Gupta B., and Torchilin V.P. Transactivating transcriptional activator-mediated drug delivery. Expert Opin Drug Deliv 3 2 (2006) 177-190
11. Dietz G.P., and Bähr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 27 2 (2004) 85-91
12. Schwarze S.R., Ho A., Vocero-Akbani A., and Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 5433 (1999) 1569-1572
13. Chauhan A., Tikoo A., Kapur A.K., and Singh M. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J Control Release 117 2 (2007) 148-162
14. Mitsui H., Inozume T., Kitamura R., Shibagaki N., and Shimada S. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity. J Invest Dermatol 126 8 (2006) 1804-1812
15. Kim S.G., Park M.Y., Kim C.H., Sohn H.J., Kim H.S., Park J.S., et al. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination. Vaccine 26 50 (2008) 6433-6440
16. Schirmbeck R., Riedl P., Zurbriggen R., Akira S., and Reimann J. Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9-dependent, but CD4+ T cell help-independent, priming of CD8+ T cells. J Immunol 171 (2003) 5198-5207
17. Shibagaki N., and Udey M.C. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur J Immunol 33 4 (2003) 850-860
18. Cao T., Lazdina U., Desombere I., Vanlandschoot P., Milich D.R., Sällberg M., et al. Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model. J Virol 75 14 (2001) 6359-6366
19. Tang T.J., de Man R.A., Kusters J.G., Kwekkeboom J., Hop W.C., van der Molen R.G., et al. Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients. J Med Virol 72 2 (2004) 215-222
20. Löhr H.F., Gerken G., Schlicht H.J., Meryer zum Büschenfelde K.H., and Fleischer B. Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B. J Infect Dis 168 5 (1993) 1133-1139
21. Chen W., Shi M., Shi F., Mao Y., Tang Z., Zhang B., et al. HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes. Hepatol Res 39 4 (2009) 355-365
22. Chen X., Yu Y., Pan Q., Tang Z., Han J., and Zang G. Enhancement of cytotoxic T lymphocyte activity by dendritic cells loaded with Tat-protein transduction domain-fused hepatitis B virus core antigen. Acta Biochim Biophys Sin 40 12 (2008) 996-1004
23. Guidotti L.G., Matzke B., Schaller H., and Chisari F.V. High-level hepatitis B virus replication in transgenic mice. J Virol 69 10 (1995) 6158-6169
24. Peng M., Chen M., Ling N., Xu H., Qing Y., and Ren H. Novel vaccines for the treatment of chronic HBV infection based on mycobacterial heat shock protein 70. Vaccine 24 7 (2006) 887-896
25. Huang Y., Chen Z., Jia H., Wu W., Zhong S., and Zhou C. Induction of Tc1 response and enhanced cytotoxic T lymphocyte activity in mice by dendritic cells transduced with adenovirus expressing HBsAg. Clin Immunol 119 3 (2006) 280-290
26. Shimazaki K., Urabe M., Monahan J., Ozawa K., and Kawai N. Adeno-associated virus vector-mediated bcl-2 gene transfer into post-ischemic gerbil brain in vivo: prospects for gene therapy of ischemia-induced neuronal death. Gene Ther 7 14 (2000) 1244-1249
27. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 5492 (2000) 767-773
28. Check E. Gene therapy: shining hopes dented-but not dashed. Nature 420 6917 (2002) 735
29. Cho H.I., Kim E.K., Park S.Y., Lee S.K., Hong Y.K., and Kim T.G. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein. Cancer Lett 258 2 (2007) 189-198
30. Justesen S., Buus S., Claesson M.H., and Pedersen A.E. Addition of TAT protein transduction domain and GrpE to human p53 provides soluble fusion proteins that can be transduced into dendritic cells and elicit p53-specific T-cell responses in HLA-A*0201 transgenic mice. Immunology 122 3 (2007) 326-334
31. Milich D.R., Schödel F., Hughes J.L., Jones J.E., and Peterson D.L. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol 71 3 (1997) 2192-2201
32. Tolia N.H., and Joshua-Tor L. Strategies for protein coexpression in Escherichia coli. Nat Methods 3 1 (2006) 55-64
33. Bertoletti A., and Gehring A.J. The immune response during hepatitis B virus infection. J Gen Virol 87 6 (2006) 1439-1449
34. Roh S., and Kim K. Overcoming tolerance in hepatitis B virus transgenic mice: a possible involvement of regulatory T cells. Microbiol Immunol 47 6 (2003) 453-460
35. Akbar S.K., and Onji M. Hepatitis B virus (HBV)-transgenic mice as an investigative tool to study immunopathology during HBV infection. Int J Exp Pathol 79 5 (1998) 279-291